Aurobac Therapeutics presents its R&D strategy & pipeline and announces new development program with Boehringer Ingelheim

  • Aurobac Therapeutics to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens.

Lyon, France, 03 June, 2024
Aurobac Therapeutics, a biopharmaceutical company founded by Boehringer Ingelheim, bioMérieux and Evotec, presented its strategy for the first time today. It aims to address high unmet medical needs associated with infections in acute hospital settings, amidst the growing antimicrobial resistance (AMR) epidemic. Aurobac Therapeutics' R&D strategy addresses this urgent need with patient- and pathogen-targeted programs. They are designed to tackle both the causes and consequences of potentially life-threatening bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) and sepsis. The adoption of innovative diagnostic strategies developed in partnership with bioMérieux is a central element to this strategy that will enable patient stratification and optimization of treatment outcomes.

In this context, Aurobac announced a new collaboration and license agreement on a Boehringer Ingelheim compound that will be developed as ATX101 for the treatment of septic shock. ATX101 is a potential first-in-class therapeutic that targets the loss of vascular integrity in septic shock. Building on promising preclinical data, Aurobac Therapeutics plans to take ATX101 into clinical development in 2025.

To continue reading, please follow this link to Aurobac's press release.